Barclays PLC Grows Stock Position in ChromaDex Co. (NASDAQ:CDXC)

Barclays PLC increased its holdings in ChromaDex Co. (NASDAQ:CDXC) by 322.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 70,072 shares of the company’s stock after acquiring an additional 53,472 shares during the period. Barclays PLC owned approximately 0.09% of ChromaDex worth $256,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its stake in shares of ChromaDex by 170.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 190,442 shares of the company’s stock valued at $520,000 after purchasing an additional 119,915 shares during the last quarter. BSW Wealth Partners purchased a new stake in shares of ChromaDex in the 3rd quarter valued at approximately $324,000. BNP Paribas Financial Markets lifted its stake in ChromaDex by 1,885.7% during the third quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company’s stock worth $267,000 after purchasing an additional 69,582 shares in the last quarter. State Street Corp grew its stake in shares of ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after buying an additional 62,692 shares in the last quarter. Finally, Rhumbline Advisers purchased a new stake in shares of ChromaDex in the 2nd quarter valued at $124,000. Institutional investors and hedge funds own 15.41% of the company’s stock.

ChromaDex Price Performance

CDXC opened at $5.94 on Tuesday. ChromaDex Co. has a 12 month low of $1.36 and a 12 month high of $7.97. The stock has a market capitalization of $453.72 million, a price-to-earnings ratio of 594.59 and a beta of 2.21. The business has a fifty day moving average price of $6.32 and a 200 day moving average price of $4.49.

ChromaDex (NASDAQ:CDXC) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share (EPS) for the quarter. ChromaDex had a net margin of 1.62% and a return on equity of 4.85%. The company had revenue of $25.58 million during the quarter, compared to the consensus estimate of $23.70 million. During the same quarter in the previous year, the firm earned ($0.01) earnings per share. On average, research analysts anticipate that ChromaDex Co. will post 0.04 earnings per share for the current year.

Insider Buying and Selling

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now owns 244,179 shares in the company, valued at $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.64% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on CDXC. Roth Mkm raised their target price on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. StockNews.com lowered shares of ChromaDex from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, January 15th. Finally, HC Wainwright upped their target price on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, November 4th.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.